Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Discussing the BTK inhibitor landscape for CLL and SLL with a focus on the Phase 3 AMPLIFY study of acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo

Ticker(s): BGNE, AZN, NRIX

Who's the expert?

Institution: Mount Sinai

Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai.
Currently manages ~250 patients with CLL and SLL and 70 patients with Hodgkin Lymphoma.
Research areas of focus include Lymphoma immunotherapy and B-cell receptor signaling inhibitors (e.g. PI3K, mTOR, BTK)

Interview Goal

On this call we will be discussing the developing Bruton tyrosine kinase (BTK) inhibitor landscape for CLL and SLL with a primary focus on the recent data from the Phase 3 AMPLIFY study of Acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo presented at ASH 2024. We will also be discussing BTK Degraders NX-5948 vs. BGB-16673.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.